Phil McEwan

List of Publications by Year
in descending order

68 papers	2,252 citations	201385 27 h-index	233125 45 g-index
69 all docs	69 docs citations	69 times ranked	2422 citing authors

#	Article	IF	Citations
1	Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Current Medical Research and Opinion, 2006, 22, 1523-1534.	0.9	236
2	Review of Utility Values for Economic Modeling in Type 2 Diabetes. Value in Health, 2014, 17, 462-470.	0.1	165
3	Validation of the IMS CORE Diabetes Model. Value in Health, 2014, 17, 714-724.	0.1	163
4	Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of <scp>DAPA‐HF</scp>. European Journal of Heart Failure, 2020, 22, 2147-2156.	2.9	91
5	Predicting atrial fibrillation in primary care using machine learning. PLoS ONE, 2019, 14, e0224582.	1.1	88
6	The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology, 2013, 58, 54-64.	3.6	71
7	Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Current Medical Research and Opinion, 2006, 22, 121-129.	0.9	69
8	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value in Health, 2018, 21, 724-731.	0.1	63
9	Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21Â334 patients in the UK. ESC Heart Failure, 2019, 6, 280-290.	1.4	57
10	The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes—A Systematic Literature Review. International Journal of Nephrology, 2020, 2020, 1-21.	0.7	51
11	Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation. Pharmacoeconomics, 2017, 35, 1257-1270.	1.7	49
12	Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre. Journal of Hepatology, 2015, 63, 797-804.	1.8	42
13	Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model. Applied Health Economics and Health Policy, 2013, 11, 53-63.	1.0	40
14	Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany. Clinical Drug Investigation, 2012, 32, 189-202.	1.1	38
15	Cost-effectiveness of saxagliptin (OnglyzaÂ®) in type 2 diabetes in Sweden. Primary Care Diabetes, 2012, 6, 127-136.	0.9	37
16	Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of TypeÂ2 Diabetes Mellitus in the Netherlands. Clinical Drug Investigation, 2014, 34, 135-146.	1.1	37
17	Cost-effectiveness of dapagliflozin (ForxigaÂ®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes, 2015, 9, 39-47.	0.9	36
18	Associations between serum potassium and adverse clinical outcomes: A systematic literature review. International Journal of Clinical Practice, 2020, 74, e13421.	0.8	36

#	ARTICLE	IF	CITATIONS
19	A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrology, 2018, 19, 37.	0.8	34
20	Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. BMC Nephrology, 2018, 19, 211.	0.8	34
21	Assessing the cost–effectiveness of sodium–glucose cotransporter–2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real–world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 2364-2374.	2.2	33
22	Evaluation of the Cost Effectiveness of Sirolimus versus Tacrolimus for Immunosuppression Following Renal Transplantation in the UK. Pharmacoeconomics, 2006, 24, 67-79.	1.7	32
23	The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Current Medical Research and Opinion, 2007, 23, S33-S39.	0.9	29
24	Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. PLoS ONE, 2017, 12, e0167770.	1.1	29
25	The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Current Medical Research and Opinion, 2007, 23, S41-S48.	0.9	28
26	The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics, 2019, 37, 1305-1312.	1.7	28
27	Evaluation of the cost-effectiveness of Sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom. Clinical Therapeutics, 2005, 27, 1834-1846.	1.1	27
28	Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Current Medical Research and Opinion, 2007, 23, S21-S31.	0.9	27
29	Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Current Medical Research and Opinion, 2007, 23, S7-S19.	0.9	26
30	Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting. Pharmacoeconomics, 2016, 34, 953-966.	1.7	25
31	The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrology, 2019, 20, 31.	0.8	24
32	Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost–effectiveness analysis utilising <scp>AFFIRM–AHF</scp>. European Journal of Heart Failure, 2021, 23, 1687-1697.	2.9	23
33	Estimating the cost–effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatology Research, 2016, 46, 423-433.	1.8	22
34	Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C. PLoS ONE, 2015, 10, e0117334.	1.1	21
35	Assessing the Relationship between Computational Speed and Precision. Pharmacoeconomics, 2010, 28, 665-674.	1.7	20
36	The cost–effectiveness of dapagliflozin in treating high–risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE–TIMI 58 trial. Diabetes, Obesity and Metabolism, 2021, 23, 1020-1029.	2.2	19

#	Article	IF	Citations
37	The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland. Diabetes Technology and Therapeutics, 2012, 14, 65-73.	2.4	18
38	The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. European Journal of Gastroenterology and Hepatology, 2016, 28, 173-180.	0.8	18
39	Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. PLoS ONE, 2015, 10, e0125846.	1.1	16
40	Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value in Health Regional Issues, 2014, 3, 136-145.	0.5	15
41	Burden of Illness in UK Subjects with Reported Respiratory Infections Vaccinated or Unvaccinated against Influenza: A Retrospective Observational Study. PLoS ONE, 2015, 10, e0134928.	1.1	15
42	Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. Journal of Medical Economics, 2019, 22, 531-544.	1.0	15
43	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
44	Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach. Value in Health Regional Issues, 2019, 18, 36-46.	0.5	14
45	Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. Contemporary Clinical Trials, 2020, 99, 106191.	0.8	14
46	Estimating Cost-Effectiveness in Type 2 Diabetes. Medical Decision Making, 2015, 35, 660-670.	1.2	13
47	Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 139-154.	0.7	13
48	The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. Diabetes Therapy, 2016, 7, 825-845.	1.2	12
49	External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions. Pharmacoeconomics, 2020, 38, 1123-1133.	1.7	11
50	Patterns of graft and patient survival following renal transplantation and evaluation of serum creatinine as a predictor of survival: a review of data collected from one clinical centre over 34 years. Current Medical Research and Opinion, 2005, 21, 1793-1800.	0.9	10
51	Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK. Diabetes Therapy, 2014, 5, 567-578.	1.2	10
52	The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review. Renal Failure, 2021, 43, 241-254.	0.8	10
53	The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus. PLoS ONE, 2016, 11, e0162441.	1.1	10
54	Resource use and direct medical costs of acute respiratory illness in the UK based on linked primary and secondary care records from 2001 to 2009. PLoS ONE, 2020, 15, e0236472.	1.1	7

#	Article	IF	Citations
55	Cost‐effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Diabetes, Obesity and Metabolism, 2020, 22, 1047-1055.	2.2	6
56	Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme. Diabetes, Obesity and Metabolism, 2020, 22, 857-865.	2.2	6
57	An alternative approach to modelling <scp>HbA1c</scp> trajectories in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 628-634.	2.2	5
58	A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective. European Journal of Gastroenterology and Hepatology, 2017, 29, 208-214.	0.8	5
59	Serum potassium as a predictor of adverse clinical outcomes in patients with increasing comorbidity burden. European Heart Journal Quality of Care & Clinical Outcomes, 2020, , .	1.8	5
60	Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. CKJ: Clinical Kidney Journal, 2022, 15, 758-770.	1.4	5
61	Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan. Value in Health Regional Issues, 2017, 12, 1-6.	0.5	4
62	Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions. International Journal of Clinical Practice, 2021, 75, e13941.	0.8	4
63	Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 241-252.	0.7	4
64	Clinical and cost‐effectiveness of insulin degludec: from clinical trials to clinical practice. Journal of Comparative Effectiveness Research, 2015, 4, 279-286.	0.6	3
65	Cardiorenal disease in the United States: future health care burden and potential impact of novel therapies. Journal of Managed Care & Specialty Pharmacy, 2022, , 1-10.	0.5	3
66	FP337RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2018, 33, i145-i145.	0.4	1
67	FP371RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2018, 33, i157-i157.	0.4	0
68	Authors' reply to Comment on "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions". Pharmacoeconomics, 2021, 39, 137-138.	1.7	0